Simplified reference region model for the kinetic analysis of [99mTC]TRODAT-1 binding to dopamine transporters in nonhuman primates using single-photon emission tomography

European Journal of Nuclear Medicine

Volumn 26, Issue 5, 1999, Pages 518-526

  Acton, Paul D ^a   Kushner, Steven A ^a   Kung, Mei Ping ^a   Mozley, P David ^a   Plössl, Karl ^a   Kung, Hank F ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Dopamine transporters; Kinetic modeling; Single photon emission tomography; Striatum; Technetium

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER; RADIOPHARMACEUTICAL AGENT;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; BABOON; CEREBELLUM; COMPARTMENT MODEL; CORPUS STRIATUM; FEMALE; HEMISPHERE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTON EMISSION TOMOGRAPHY;

ANIMALS; BRAIN; CARRIER PROTEINS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; ORGANOTECHNETIUM COMPOUNDS; PAPIO; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 0032920532     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050420     Document Type: Article

References (38)

1. 123I]IBZM in Parkinsonian syndromes. J Nucl Med 1991; 32: 1014-1015.
2. 123I]-Iodobenzamide-SPET predicts dopaminergic responsiveness in patients with de novo parkinsonism. Neurology 1992; 42:556-561.
3. 3. Oertel WH, Trenkwalder C, Gasser T, et al. Epidemiological, genetic, pharmacological, kinesiological, nuclear medical (IBZM-SPET), standard and functional MRI studies on Parkinson's disease and related disorders and economic evaluation of Parkinson's disease therapy - clinical projects in the BMFT-research program Munich: "Parkinson's disease and other basal ganglia disorders" [review]. J Neural Transm Suppl 1995; 46: 325-337.
4. 4. Schwarz J, Oertel WH, Tatsch K. Iodine-123-iodobenzamide binding in parkinsonism: reduction by dopamine agonists but not L-dopa. J Nucl Med 1996; 37: 1112-1115.
5. 5. Staffen W, Hondl N, Trinka E, Zenzmaier R, Ladurner G. SPET investigations in extrapyramidal diseases using specific ligands. Nucl Med Commun 1997; 18: 159-163.
6. 2 receptor imaging and measurement with SPET. Adv Neurol 1993; 60: 494-500.
7. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
8. 8. Asenbaum S, Bŗcke T, Pirker W, Podreka I, Angelberger P, Wenger S, Wober C, Muller C, Deecke L. Imaging of dopamine transporters with iodine-123-β-CIT and SPET in Parkinson's disease. J Nucl Med 1997; 38: 1-6.
9. 123I]IPT and single-photon emission tomography. Eur J Nucl Med 1997; 24: 415-421.
10. 123I-β-CIT single photon emission tomography in dementia of the Alzheimer type and diffuse Lewy body disease. Eur J Nucl Med 1997; 24: 320-325.
11. 11. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL. Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997; 24: 609-614.
12. 123I]β-CIT in Parkinson's disease and progressive supranuclear palsy, evaluated with single photon emission tomography. Eur J Nucl Med 1998; 25: 1270-1276.
13. 13. Kung HF, Kim H-J, Kung M-P, Meegalla SK, Plössl K, Lee H-K. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996; 23: 1527-1530.
14. 99mTc]TRODAT-1: a novel technetium-99 m complex as a dopamine transporter imaging agent. Eur J Nucl Med 1997; 24: 372-380.
15. 15. Phelps ME, Mazziotta JC, Schelbert HR. Positron emission tomography and autoradiography: principles and applications for the brain and heart. New York: Raven Press, 1986.
16. 16. Hume SP, Myers R, Bloomfield PM, Opacka-Juffry J, Cremer JE, Ahier RG, Luthra SK, Brooks DJ, Lammertsma AA. Quantitation of carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse 1992; 12: 47-54.
17. 11C]raclopride studies. J Cereb Blood Flow Metab 1996; 16: 42-52.
18. 18. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4: 153-158.
19. 19. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997; 6: 279-287.
20. 20. Meegalla SK, Pl̂ssl K, Kung M-P, Chumpradit S, Stevenson DA, Kushner SA, McElgin WT, Mozley PD, Kung HF. Synthesis and characterization of Tc-99m labeled tropanes as dopamine transporter imaging agents. J Med Chem 1997; 40: 9-17.
21. 99mTc]TRODAT-1: a novel compound for imaging the dopamine transporter. J Nucl Med 1999; 40: 150-158.
22. 22. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984; 15: 217-227.
23. 2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258-261.
24. 2-dopamine receptors studied by PET: a comparison to the equilibrium analysis. J Cereb Blood Flow Metab 1989; 9: 696-708.
25. 2 receptors with iodine-123-IBF SPET. J Nucl Med 1996; 37: 513-520.
26. 11C-N-methyl-spiperone. Acta Neurol Scand 1987; 75: 168-178.
27. 2-receptor binding with iodine-123-IBF SPET in healthy subjects. J Nucl Med 1997; 38: 31-37.
28. 28. Ashburner J, Haslam J, Taylor C, Cunningham V, Jones T. A cluster analysis approach for the characterisation of dynamic PET data. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press; 1996: 301-306.
29. 2 receptor images in schizophrenia. Eur J Nucl Med 1997; 24: 111-118.
30. 30. Meltzer CC, Leal JP, Mayberg HS, Wagner HN Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990; 14: 561-570.
31. 31. Meltzer CC, Zubieta JK, Links JM, Brakeman P, Stumpf MJ, Frost JJ. MRI based correction for PET partial volume effects in the presence of heterogeneity in gray-matter radioactivity. J Nucl Med 1994; 35.
32. 32. Mueller-Gaertner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, Davatzikos C, Frost JJ. Measurement of radiotracer concentration in brain grey matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992; 12: 571-583.
33. 33. Frost JJ, Meltzer CC, Zubieta JK, Links JM, Brakeman P, Stumpf MJ, Kruger M. MR-based correction of partial volume effects in brain PET imaging. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press; 1996: 152-157.
34. 34. Kosugi Y, Sase M, Suganami Y, Momose T, Nishikawa J. Dissolution of partial volume effect in PET by an inversion technique with the MR-embedded neural network model. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press; 1996;166-169.
35. 35. Roussel OG, Ma Y, Marenco S, Wong DF, Evans AC. In vivo correction method for partial volume effects in positron emission tomography: accuracy and precision. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press; 1996: 158-165.
36. 36. Shao L, Billings JJ, Pfeiffer N, Kung HF. Concentration recovery for SPET CNS dopamine receptor studies for monkeys. Med Phys 1994; 21: 675-681.
37. 37. Lin KP, Huang SC, Yu DC, Melega W, Barrio JR, Phelps ME. Automated image registration for FDOPA PET studies. Phys Med Biol 1996; 41: 2775-2788.
38. 38. Acton PD, Pilowsky LS, Suckling J, Brammer MJ, Ell PJ. Registration of dynamic dopamine D2 receptor images using principal component analysis. Eur J Nucl Med 1997; 24: 1405-1412.